Prelude Therapeutics Incorporated (PRLD)
PRLDNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$3.76
+0.1600 (+4.44%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $300.06m
- P/E
- –
- EPS, last 4 quarters
- $-0.7300
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.17 to $6.83
- Average volume
- 457.4k
- Previous close
- $3.60
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $10.00, +166.0% from here
Earnings
next estimate $-0.1400Next report Nov 11, 2026
Sep 2025
+25.7%
Dec 2025
+39.4%
Mar 2026
+51.9%
Jun 2026
+17.6%
estimate reported, and the surprise
Financials
| Quarter | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | $4.58m | $5.70m |
| Gross profit | – | – | $4.58m | $5.70m |
| Operating income | -$34.61m | -$32.19m | -$14.18m | -$15.45m |
| Net income | -$32.09m | -$31.23m | -$10.38m | -$13.92m |
News
8 latest- Earnings Preview: Merck KGaA (MKKGY) Q3 Earnings Expected to DeclineZacks · 5 days ago
- Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · 6 days ago
- Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Zacks · Oct 27, 2026
- Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte OptionMarketBeat · Oct 22, 2026
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data RTTNews · Oct 16, 2026
- Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround Zacks · Oct 16, 2026
- Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial RTTNews · Oct 13, 2026
The company
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- preludetx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.